the more I read the recent news the better it gets:
CHRI generated 2,7 mln USd net with revenues of 10,..mln USD.
This new drug is expected to generate about 18 mln USD revenue annually, and is one of the highest prices (margined ?) herbs in TCM.
So with a margin of 20% assumed for CHRI(perhaps slightly lower than angelica)they may add 3,6 mln in net earnings in 2012, and perhaps half of that in 2011.
An estimate of 0,04 eps in 2011 now seems quite conservative to me, and in 2012 we may well pass 0,06 cent per share, without dilution necessary
wow !
